For example, a 2011 study in rats found that the peptide successfully healed various lesions and promoted healthy weight gain in models of short-bowel syndrome.14 Additionally, as researchers note in the aforementioned 2016 review on BPC-157 and the gut-brain axis, BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Its also written in the review that the peptide acts as a mediator of Roberts cytoprotection, defined as the counteraction of the lesions arising from direct detrimental contact with a noxious agent.7 15 Insider Tip: Though there has been some small-scale positive human research on BPC-157, most of the peptides potential uses are based on the outcomes of animal or cell studies
The certainty of results is moderate, indicating a possible benefit of L-carnitine in this context
While preclinical data on the peptide BPC-157 reveals profound therapeutic potential, clinicians are left navigating a landscape where robust human trials are conspicuously absent
Other weight loss medications in trials Cagrilintides potential value isnt about having the highest weight-loss percentage in the field
Presented for research literature review only Semenova N et al
For Smith-Reed, relief came in the form of a synthetic peptide known as PT141, also called bremelanotide